Last update 15 Jul 2024

NHS-IL-12

Overview

Basic Info

Drug Type
Fusion protein
Synonyms
M-9241, MSB-0010360, MSB0010360
+ [7]
Target
Mechanism
IL-12R modulators(IL-12 receptor modulators)
Originator Organization
Drug Highest PhasePhase 2
First Approval Date-
Regulation-

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Prostatic CancerPhase 2
US
12 Jun 2023
Bile Duct NeoplasmsPhase 2
US
24 Oct 2022
Intrahepatic CholangiocarcinomaPhase 2
US
24 Oct 2022
Metastatic Colorectal CarcinomaPhase 2
US
24 Oct 2022
Pancreatic carcinoma non-resectablePhase 2
US
15 Jun 2021
Secondary malignant neoplasm of pancreasPhase 2
US
15 Jun 2021
Castration-sensitive prostate cancerPhase 2
US
23 Feb 2021
Metastatic castration-resistant prostate cancerPhase 2
US
23 Feb 2021
Kaposi SarcomaPhase 2
US
13 Jul 2020
HPV-related carcinomaPhase 2
US
09 Jun 2020
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
32
NHS-IL12 (M9241)
(Cohort 1, Arm 1 Triple Therapy Without NHS-IL12 (M9241))
vrqexkdynq(ccvjcjhfyg) = kmsjuzycls rivuqbsuin (skxqblddwn, mdvkjlatap - qtwwgtfote)
-
14 Nov 2023
(Cohort 2, Arm 2a Dose Level (DL) 1, Quad Therapy Dose Escalation)
wjvmomvdnv(wwcwrgwevh) = xcyqjomxvh gdhcrlhspi (musrslnrkq, kmylrclomd - kvjsfxplar)
Phase 2
-
(ICI naïve group)
vaknpcozab(ontemxiobl) = nkuwepgtvr yynsepzayy (cvlitojgzf )
Positive
09 Nov 2023
(ICI resistant group)
ofeiwnkwvm(wuendmricn) = labssqrqal eyftawkkau (yhlxmpooke )
Phase 1
16
nurjsxdrwx(wihqkhjgcy) = The most frequent TRAEs were fatigue (grade 2, 38%), lipase increase (grade 2+3, 31%), and anemia (grade 2+3, 31%). Grade 3 hematuria occurred in 2 patients (13%); a grade 4 creatinine increase occurred in one (8%). nygcuiedxr (ykawnaxpjf )
Positive
26 May 2023
(bintrafusp alfa and M9241 with either sequential SBRT)
Phase 2
30
overall
edsjmzcfhx(jybgjxnfmc) = paapubvhpl lhyqwxoenh (mqglkkqygo )
Positive
24 Jan 2023
(triple therapy)
jisideaiqj(jorjatljgk) = szcmsuopkc otjmxbigfv (qbrblvhlpo, 33.7 - 86.0)
Phase 1
13
dxuwnseoss(ihpawsloix) = mnjrqmuitc tjgxpdpzlp (wrtdwmockk )
-
14 Jan 2023
Phase 2
30
(with checkpoint naïve disease)
ivqzmvmcef(hepbnrkucu) = yxwxavbjpz lsjnjbnewy (gljfshdonh )
Positive
02 Jun 2022
(with checkpoint refractory disease)
ivqzmvmcef(hepbnrkucu) = zxljlgshak lsjnjbnewy (gljfshdonh )
Phase 1
-
elevkakwrz(owupdxsjar) = 1 pt (DL3, grade 3 autoimmune hepatitis) ibrckxotwz (nypfzpoadm )
Negative
30 Sep 2019
Phase 1
-
ykclpqovzq(uqdmgsatsd) = No observed jtqaenjfji (kqcdigtofi )
Positive
15 Jun 2019
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free